Masso Torrence Wealth Management Inc. Corvus Pharmaceuticals, Inc. Transaction History
Masso Torrence Wealth Management Inc.
- $218 Million
- Q3 2025
A detailed history of Masso Torrence Wealth Management Inc. transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Masso Torrence Wealth Management Inc. holds 17,000 shares of CRVS stock, worth $136,680. This represents 0.06% of its overall portfolio holdings.
Number of Shares
17,000
Previous 50,000
66.0%
Holding current value
$136,680
Previous $200,000
39.5%
% of portfolio
0.06%
Previous 0.1%
Shares
7 transactions
Others Institutions Holding CRVS
# of Institutions
104Shares Held
38.9MCall Options Held
98.5KPut Options Held
226K-
Orbimed Advisors LLC San Diego, CA7.17MShares$57.6 Million1.02% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.04MShares$56.6 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.28MShares$26.4 Million0.0% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$26.3 Million9.69% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$21.5 Million0.16% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $374M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...